BioLife Solutions, Inc.
BLFSHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeBioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The $1.23B market capitalization puts BLFS squarely in small-cap range for its industry. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Market Cap
$1.23B
Beta
1.97
P/E (TTM)
—
P/E (Fwd)
87.07
EPS (TTM)
$-0.24
EPS (Fwd)
$0.29
ROE
-3.1%
ROA
-0.1%
Cash
$81.0M
Total Debt
$14.9M
Free CF
$6.4M
52W Change
15.4%
Annual Financials
Cash vs Debt
With $81.0M in cash and $14.9M in debt, BLFS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $6.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -3.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $76.2M (2022) to $96.2M (2025), reflecting a 26% increase over the period.
BioLife Solutions, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BLFS.